|
121 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2334 News |
|
| «12...2223242526272829303132...4647» |
- ||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Trial initiation date: STAR Extension: Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (clinicaltrials.gov) - May 18, 2014
P3, N=1770, Recruiting, Sponsor: H. Lundbeck A/S
Initiation date: Mar 2014 --> Apr 2014
- ||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment change: STAR Extension: Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (clinicaltrials.gov) - May 18, 2014
P3, N=1770, Recruiting, Sponsor: H. Lundbeck A/S
Initiation date: Mar 2014 --> Apr 2014 N=2490 --> 1770
- | S-equol (AUS-131) / Ausio Pharma
New P1 trial: S-Equol in Alzheimer's Disease (SEAD) Trial (clinicaltrials.gov) - May 18, 2014
P1, N=15, Not yet recruiting, Sponsor: Russell Swerdlow, MD
- |||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment open: STAR Extension: Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (clinicaltrials.gov) - May 18, 2014
P3, N=1770, Recruiting, Sponsor: H. Lundbeck A/S
N=2490 --> 1770 Not yet recruiting --> Recruiting
- donepezil / Generic mfg.
Trial termination: A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - May 15, 2014
P1, N=9, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting Completed --> Terminated; This study terminated 27Apr2010 due to slow recruitment and the need to use the existing information to determine dosing for another study.
- Trial primary completion date: Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel (clinicaltrials.gov) - May 14, 2014
P=N/A, N=150, Recruiting, Sponsor: Uniformed Services University of the Health Sciences
Completed --> Terminated; This study terminated 27Apr2010 due to slow recruitment and the need to use the existing information to determine dosing for another study. Trial primary completion date: Mar 2014 --> Mar 2015
- Trial completion date: Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel (clinicaltrials.gov) - May 14, 2014
P=N/A, N=150, Recruiting, Sponsor: Uniformed Services University of the Health Sciences
Trial primary completion date: Mar 2014 --> Mar 2015 Trial completion date: Feb 2015 --> Feb 2016
- Trial completion: Therapy for Reading Problems in Adults After Brain Injury (clinicaltrials.gov) - May 14, 2014
P=N/A, N=58, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial completion date: Feb 2015 --> Feb 2016 Recruiting --> Completed
- rilapladib (SB-659032) / GSK
Trial completion date: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (clinicaltrials.gov) - May 14, 2014
P1, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial completion date: Aug 2014 --> Sep 2014
- Victoza (liraglutide) / Novo Nordisk
Clinical: Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes (clinicaltrials.gov) - May 14, 2014
P=N/A, N=80, Recruiting, Sponsor: Stanford University
- Trial primary completion date, HEOR: Comparative Effectiveness of Dementia Care Strategies in Underserved Communities (clinicaltrials.gov) - May 13, 2014
P=N/A, N=144, Completed, Sponsor: RAND
Trial completion date: Aug 2014 --> Sep 2014 Trial primary completion date: Aug 2013 --> Oct 2013
- Trial completion date, HEOR: Comparative Effectiveness of Dementia Care Strategies in Underserved Communities (clinicaltrials.gov) - May 13, 2014
P=N/A, N=144, Completed, Sponsor: RAND
Trial primary completion date: Aug 2013 --> Oct 2013 Trial completion date: Aug 2013 --> Oct 2013
- Enrollment change, HEOR: Comparative Effectiveness of Dementia Care Strategies in Underserved Communities (clinicaltrials.gov) - May 13, 2014
P=N/A, N=144, Completed, Sponsor: RAND
Trial completion date: Aug 2013 --> Oct 2013 N=250 --> 144
- Trial completion, HEOR: Comparative Effectiveness of Dementia Care Strategies in Underserved Communities (clinicaltrials.gov) - May 13, 2014
P=N/A, N=144, Completed, Sponsor: RAND
N=250 --> 144 Enrolling by invitation --> Completed
- donepezil / Generic mfg.
Trial primary completion date: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - May 13, 2014
P2, N=36, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed Trial primary completion date: Nov 2015 --> Dec 2015
- | donepezil / Generic mfg.
Trial initiation date: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - May 13, 2014
P2, N=36, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2015 --> Dec 2015 Initiation date: Mar 2014 --> Apr 2014
- donepezil / Generic mfg.
Trial completion date: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - May 13, 2014
P2, N=36, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Mar 2014 --> Apr 2014 Trial completion date: Nov 2015 --> Feb 2016
- Clinical: IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment (clinicaltrials.gov) - May 13, 2014
P=N/A, N=589, Completed, Sponsor: University of Roma La Sapienza
- | donepezil / Generic mfg.
Enrollment open: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - May 13, 2014
P2, N=36, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Nov 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- Trial primary completion date: Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (clinicaltrials.gov) - May 12, 2014
P3, N=650, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Jan 2016
- Trial completion date: Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (clinicaltrials.gov) - May 12, 2014
P3, N=650, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2016 --> Jan 2016 Trial completion date: Jun 2016 --> Jan 2016
- ||| sembragiline (RO4602522) / Roche, Evotec
Enrollment closed: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - May 11, 2014
P2, N=544, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2016 --> Jan 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - May 11, 2014
P4, N=70, Recruiting, Sponsor: Gelderse Vallei Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jun 2016
- Trial completion date: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - May 11, 2014
P4, N=70, Recruiting, Sponsor: Gelderse Vallei Hospital
Trial primary completion date: Jun 2014 --> Jun 2016 Trial completion date: Jun 2014 --> Jun 2016
- Enrollment change: Nicotine Replacement Therapy in the Intensive Care Unit (clinicaltrials.gov) - May 11, 2014
P4, N=70, Recruiting, Sponsor: Gelderse Vallei Hospital
Trial completion date: Jun 2014 --> Jun 2016 N=100 --> 70
- modafinil / Generic mfg.
Enrollment open: Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill (clinicaltrials.gov) - May 11, 2014
P3, N=30, Recruiting, Sponsor: Brigham and Women's Hospital
N=100 --> 70 Not yet recruiting --> Recruiting
- || rivastigmine / Generic mfg.
Trial primary completion date: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - May 11, 2014
P4, N=186, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> May 2015
- ||| rivastigmine / Generic mfg.
Trial initiation date: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - May 11, 2014
P4, N=186, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> May 2015 Initiation date: Oct 2013 --> Jul 2014
- || rivastigmine / Generic mfg.
Trial completion date: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - May 11, 2014
P4, N=186, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2013 --> Jul 2014 Trial completion date: Sep 2014 --> May 2015
- Trial primary completion date: AWAKE: Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics (clinicaltrials.gov) - May 8, 2014
P=N/A, N=26, Completed, Sponsor: University Medical Center Nijmegen
Trial completion date: Sep 2014 --> May 2015 Trial primary completion date: Oct 2011 --> Sep 2013
- Trial completion date: AWAKE: Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics (clinicaltrials.gov) - May 8, 2014
P=N/A, N=26, Completed, Sponsor: University Medical Center Nijmegen
Trial primary completion date: Oct 2011 --> Sep 2013 Trial completion date: Oct 2011 --> Sep 2013
- Enrollment change: AWAKE: Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics (clinicaltrials.gov) - May 8, 2014
P=N/A, N=26, Completed, Sponsor: University Medical Center Nijmegen
Trial completion date: Oct 2011 --> Sep 2013 N=12 --> 26
- Trial completion: AWAKE: Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics (clinicaltrials.gov) - May 8, 2014
P=N/A, N=26, Completed, Sponsor: University Medical Center Nijmegen
N=12 --> 26 Recruiting --> Completed
- epothilone D (BMS-241027) / BMS
Biomarker, Trial primary completion date: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - May 6, 2014
P1, N=40, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2013
- epothilone D (BMS-241027) / BMS
Biomarker, Trial completion date: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - May 6, 2014
P1, N=40, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2014 --> Oct 2013 Trial completion date: Oct 2014 --> Oct 2013
- epothilone D (BMS-241027) / BMS
Biomarker, Enrollment change: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - May 6, 2014
P1, N=40, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Oct 2014 --> Oct 2013 N=100 --> 40
- | New P1/2 trial: Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P1/2, N=53, Not yet recruiting, Sponsor: Oregon Health and Science University
- | epothilone D (BMS-241027) / BMS
Biomarker, Trial completion: Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - May 6, 2014
P1, N=40, Completed, Sponsor: Bristol-Myers Squibb
N=100 --> 40 Recruiting --> Completed
- Clinical: POD-I: Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients (clinicaltrials.gov) - May 4, 2014
P=N/A, N=400, Recruiting, Sponsor: Chiang Mai University
- Trial primary completion date: 2-StaLi: Cognitive Outcome After Two-stage Liver-Operation (clinicaltrials.gov) - May 4, 2014
P=N/A, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed Trial primary completion date: Feb 2014 --> Feb 2015
- Trial completion date: 2-StaLi: Cognitive Outcome After Two-stage Liver-Operation (clinicaltrials.gov) - May 4, 2014
P=N/A, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Feb 2014 --> Feb 2015 Trial completion date: Feb 2015 --> Feb 2016
- Clinical: Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine (clinicaltrials.gov) - May 4, 2014
P=N/A, N=10, Not yet recruiting, Sponsor: Mayo Clinic
- Trial primary completion date: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - May 4, 2014
P=N/A, N=5, Recruiting, Sponsor: Duke University
Trial completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Oct 2013 --> Oct 2015
- Trial completion date: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - May 4, 2014
P=N/A, N=5, Recruiting, Sponsor: Duke University
Trial primary completion date: Oct 2013 --> Oct 2015 Trial completion date: Oct 2013 --> Oct 2015
- | rilapladib (SB-659032) / GSK
New P1 trial: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (clinicaltrials.gov) - May 2, 2014
P1, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- || Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Trial primary completion date: Attention & Memory Impairments in Menopausal Women (clinicaltrials.gov) - May 1, 2014
P4, N=57, Completed, Sponsor: University of Pennsylvania
Trial completion date: Oct 2013 --> Oct 2015 Trial primary completion date: Dec 2013 --> Apr 2014
- || Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Trial completion date: Attention & Memory Impairments in Menopausal Women (clinicaltrials.gov) - May 1, 2014
P4, N=57, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Dec 2013 --> Apr 2014 Trial completion date: Jan 2014 --> Apr 2014
- ||| Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Enrollment change: Attention & Memory Impairments in Menopausal Women (clinicaltrials.gov) - May 1, 2014
P4, N=57, Completed, Sponsor: University of Pennsylvania
Trial completion date: Jan 2014 --> Apr 2014 N=34 --> 57
- |||| Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Trial completion: Attention & Memory Impairments in Menopausal Women (clinicaltrials.gov) - May 1, 2014
P4, N=57, Completed, Sponsor: University of Pennsylvania
N=34 --> 57 Active, not recruiting --> Completed
- Biomarker: Olfactory Neuroepithelial Tissue of Alzheimer Disease (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=40, Recruiting, Sponsor: Seoul National University Hospital